Quarterly report pursuant to Section 13 or 15(d)

Other Income / (Expense)

v3.23.3
Other Income / (Expense)
3 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Other Income / (Expense)

Note 11. Other Income / (Expense):

The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands):

Quarter Ended

September 30, 

    

2023

    

2022

Interest expense

$

(4,893)

$

(3,790)

Interest income

890

433

Gain (loss) on investment(1)

283

49,769

Gain (loss) on equity method investment

(2,290)

Other non-operating income (expense), net

 

(294)

 

987

Total other income (expense)

$

(6,304)

$

47,399

(1) Primarily due to a $0.3 million gain on the sale of our exchange traded investment grade bond funds during the quarter ended September 30, 2023 compared to a $37.2 million gain on the sale of our ChemoCentryx investment and a $11.7 million gain on the sale of Eminence in the quarter ended September 30, 2022.